Lumican Accumulates with Fibrillar Collagen in Fibrosis in Hypertrophic Cardiomyopathy
ESC Heart Failure · 01.04.2023 · 10 (2) · 858-871
DOI: 10.1002/ehf2.14234 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 29.11.2022. Verfasst von Chloe Rixon und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Experimental Medical Research, Oslo University Hospital Ullevål and University of Oslo, Oslo, Norway. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Heart Failure, Cardiomyopathies. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Norwegian Health Association, Research Council of Norway, Anders Jahre's Fund for the Promotion of Science.
Abstract (Originalsprache)
Aims
Familial hypertrophic cardiomyopathy (HCM) is the most common form of inherited cardiac disease. It is characterized by myocardial hypertrophy and diastolic dysfunction, and can lead to severe heart failure, arrhythmias, and sudden cardiac death. Cardiac fibrosis, defined by excessive accumulation of extracellular matrix (ECM) components, is central to the pathophysiology of HCM. The ECM proteoglycan lumican is increased during heart failure and cardiac fibrosis, including HCM, yet its role in HCM remains unknown. We provide an in-depth assessment of lumican in clinical and experimental HCM.
Methods
Left ventricular (LV) myectomy specimens were collected from patients with hypertrophic obstructive cardiomyopathy (n = 15), and controls from hearts deemed unsuitable for transplantation (n = 8). Hearts were harvested from a mouse model of HCM; Myh6 R403Q mice administered cyclosporine A and wild-type littermates (n = 8–10). LV tissues were analysed for mRNA and protein expression. Patient myectomy or mouse mid-ventricular sections were imaged using confocal microscopy, direct stochastic optical reconstruction microscopy (dSTORM), or electron microscopy. Human foetal cardiac fibroblasts (hfCFBs) were treated with recombinant human lumican (n = 3) and examined using confocal microscopy.
Results
Lumican mRNA was increased threefold in HCM patients (P < 0.05) and correlated strongly with expression of collagen I (R2 = 0.60, P < 0.01) and III (R2 = 0.58, P < 0.01). Lumican protein was increased by 40% in patients with HCM (P < 0.01) and correlated with total (R2 = 0.28, P = 0.05) and interstitial (R2 = 0.30, P < 0.05) fibrosis. In mice with HCM, lumican mRNA increased fourfold (P < 0.001), and lumican protein increased 20-fold (P < 0.001) in insoluble ECM lysates. Lumican and fibrillar collagen were located together throughout fibrotic areas in HCM patient tissue, with increased co-localization measured in patients and mice with HCM (patients: +19%, P < 0.01; mice: +13%, P < 0.01). dSTORM super-resolution microscopy was utilized to image interstitial ECM which had yet to undergo overt fibrotic remodelling. In these interstitial areas, collagen I deposits located closer to (−15 nm, P < 0.05), overlapped more frequently with (+7.3%, P < 0.05) and to a larger degree with (+5.6%, P < 0.05) lumican in HCM. Collagen fibrils in such deposits were visualized using electron microscopy. The effect of lumican on collagen fibre formation was demonstrated by adding lumican to hfCFB cultures, resulting in thicker (+53.8 nm, P < 0.001), longer (+345.9 nm, P < 0.001), and fewer (−8.9%, P < 0.001) collagen fibres.
Conclusions
The ECM proteoglycan lumican is increased in HCM and co-localizes with fibrillar collagen throughout areas of fibrosis in HCM. Our data suggest that lumican may promote formation of thicker collagen fibres in HCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Experimental Medical Research, Oslo University Hospital Ullevål and University of Oslo, Oslo, Norway.
- K.G. Jebsen Centre for Cardiac Research, University of Oslo, Oslo, Norway.
- Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- K. G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, Tromsø, Norway.
Förderung
- Norwegian Health Association
- Research Council of Norway
- Anders Jahre's Fund for the Promotion of Science
- South-Eastern Norway Regional Health Authority
- Kristian Gerhard Jebsen Foundation
- Olav Raagholt and Gerd Meidel Raagholt's Fund for Science, Norway
- Nasjonalforeningen for Folkehelsen
- Norges Forskningsråd
Zitieren
APA
Rixon, C., Andreassen, K., Shen, X., Erusappan, P. M., Almaas, V. M., Palmero, S., Dahl, C. P., Ueland, T., Sjaastad, I., Louch, W. E., Stokke, M. K., Tønnessen, T., Christensen, G., & Lunde, I. G. (2023). Lumican Accumulates with Fibrillar Collagen in Fibrosis in Hypertrophic Cardiomyopathy. ESC Heart Failure, 10(2), 858-871. https://doi.org/10.1002/ehf2.14234
Vancouver
Rixon C, Andreassen K, Shen X, Erusappan PM, Almaas VM, Palmero S, et al. Lumican Accumulates with Fibrillar Collagen in Fibrosis in Hypertrophic Cardiomyopathy. ESC Heart Failure. 2023;10(2):858-871. doi:10.1002/ehf2.14234
BibTeX
@article{Rixon2023,
author = {Rixon, Chloe and Andreassen, Kristine and Shen, Xin and Erusappan, Pugazendhi Murugan and Almaas, Vibeke Marie and Palmero, Sheryl and Dahl, Christen Peder and Ueland, Thor and Sjaastad, Ivar and Louch, William Edward and Stokke, Mathis Korseberg and Tønnessen, Theis and Christensen, Geir and Lunde, Ida Gjervold},
title = {Lumican Accumulates with Fibrillar Collagen in Fibrosis in Hypertrophic Cardiomyopathy},
journal = {ESC Heart Failure},
year = {2023},
volume = {10},
number = {2},
pages = {858--871},
doi = {10.1002/ehf2.14234}
}
EUVIMED